Journal Mobile Options
Table of Contents
Vol. 63, No. 3, 2011
Issue release date: February 2011

Antidepressive Effect of Mirtazapine in Post-Myocardial Infarction Depression Is Associated with Soluble TNF-R1 Increase: Data from the MIND-IT

Tulner D.M. · Smith O.R.F. · Schins A. · de Jonge P. · Quere M. · Delanghe J.R. · Crijns H.J. · den Boer J.A. · Korf J. · Honig A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Depressive disorder after myocardial infarction (MI) is associated with increased cardiac morbidity and mortality. Immune activity such as inflammation might be implicated as an underlying mechanism. The purpose of this study is to investigate whether the response to an antidepressant in post-MI depression is associated with changes of inflammatory markers in serum. Methods: In a double-blind placebo-controlled study with mirtazapine 30 mg/day (50 patients), the antidepressive effect was related to immune activation parameters. The cytokines interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), the soluble cytokine receptors sIL-6R, sTNF-R1 and sTNF-R2, and the inflammation-sensitive plasma proteins C-reactive protein and neopterin were assessed. Results: Subgroup analyses revealed a highly significant correlation of pronounced sTNF-R1 increase with a decrease in depressive symptoms in antidepressant responders. Conclusion: Significant effects on inflammation accompany the therapeutic efficacy of mirtazapine in contrast to the therapeutic efficacy of placebo and the nontherapeutic efficacy of mirtazapine.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC: Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006;21:30–38.
  2. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann P, Czajkowski SM, Jaffe AS, ENRICHD Investigators: Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004;66:466–474.
  3. Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR: Onset of major depression associated with acute coronary syndromes: relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry 2006;63:283–288.
  4. Honig A, Kuyper AM, Schene AH, van Melle JP, de Jonge P, Tulner DM, Schins A, Crijns HJGM, Kuijpers P, Vossen H, Lousberg R, Ormel J, MIND-IT Investigators: Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 2007;69:606–613.
  5. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007;24:297:367–379.

    External Resources

  6. De Jonge P, Honig A, van Melle JP, Schene AH, Kuijper AMG, Tulner D, Schins A, Ormel J, MIND-IT Investigators: Incomplete response to treatment for depression following myocardial infarction is associated with subsequent cardiac events. Am J Psychiatry 2007;164:1371–1378.
  7. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, Perry VH, Rousey S, Yirmiya R: Identification and treatment of symptoms associated with inflammation in medically ill patients. Psychoneuroendocrinology 2008;33:18–29.
  8. Jiang Y, Deacon R, Anthony DC, Campbell SJ: Inhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases. Neurobiol Dis 2008;32:125–132.
  9. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R, Barak O, Reichenberg A, Cohen E, Shavit Y, Ovadia H: Cytokines, ‘depression due to a general medical condition’ and antidepressant drugs; in Dantzer R, Wollmann EE, Yirmiya (eds): Illness, Cytokines, and Depression. New York, Kluwer Academic/Plenum Publishers, pp 283–316.
  10. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmächer T: Illness, cytokines, and depression. Ann NY Acad Sci 2000;917:478–487.
  11. O’Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326–331.
  12. Schins A, Tulner D, Lousberg R, Kenis G, Delanghe J, Crijns HJ, Grauls G, Stassen F, Maes M, Honig A: Inflammatory markers in depressed post-myocardial infarction patients. J Psychiatr Res 2005;39:137–144.
  13. KrausT, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T: Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002;35:220–225.
  14. Hinze-Selch D, Schuld A, Kraus T, Uhr M, Haack M, Pollmacher T: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology 2000;23:13–19.
  15. Parissis JT, Adamopoulos S, Rigas A, Kostakis Gl, Karatzas D, Venetsanou K, Kremastinos DT: Comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004;94:1326–1328.
  16. Ferketich AK, Ferguson JP, Binkley PF: Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005;150:132–136.
  17. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149–2153.
  18. McCoy MK, Tansey MG: TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008;5:45.
  19. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, Maudsley S: Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 2008;31:504–511.
  20. Bemelmans MH, van Tits LJ, Buurman WA: Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 1996;16:1–11.
  21. MacEwan DJ: TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002;14:477–492.
  22. Van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, Gans RO, Zijlstra F: Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003;92:1201–1203.
  23. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–1772.
  24. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, Cicchitelli G, Olivares A, Parrinello G, Percoco G., Guardigli G, Mele D, Pirani R, Ferrari R: Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study. Circulation 2005;111:863–870.
  25. Widner B, Laich A, Sperner-Unterweger B, Ledochowski M, Fuchs D: Neopterin production, tryptophan degradation, and mental depression – What is the link? Brain Behav Immun 2002;16:590–595.
  26. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Kloiber S, Lucae S, Ising M, Uhr M, Holsboer F, Pollmächer T: Depression, comorbidities and the TNF-α system. Eur Psychiatry 2008;23:421–429.
  27. Friebe A, Schwarz MJ, Schmid-Wendtner M, Volkenandt M, Schmidt F, Horn M, Janssen G, Schaefer M: Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J Immunother 2007;30:333–337.
  28. Moorman AJ, Mozaffarian D, Wilkinson CW, Lawler RL, McDonald GB, Crane BA, Spertus JA, Russo JE, Stempien-Otero AS, Sullivan MD, Levy WC: In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression. J Card Fail 2007;13:738–743.
  29. Gebhardt S, Heiser P, Fischer S, Schneyer T, Krieg JC, Vedde H: Relationships among endocrine and signaling-related responses to antidepressants in human monocytic U-937 blood cells: analysis of factors and response patterns. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1682–1687.
  30. Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19–25.

    External Resources

  31. Baron RM, Kenny DA: The moderator-mediator variable distinction in social psychological research: conceptual, strategic and statistical considerations. J Pers Soc Psychol 1986;51:1173–1182.
  32. Thase M: Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60(suppl 6):15–19.

    External Resources

  33. Kornstein SG: Maintenance therapy to prevent recurrence of depression: summary and implications of the PREVENT study. Expert Rev Neurother 2008;8:737–742.
  34. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM: Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther 2009;86:527–532.
  35. Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, Pollmacher T, Holsboer F, Ising M: Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60:882–888.
  36. Pan W, Kastin AJ: Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 2007;83:363–374.
  37. Levine SJ: Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem 2008;283:14177–14181.
  38. Pan W, Kastin AJ: Upregulation of the transport system for TNF-α at the blood-brain barrier. Arch Physiol Biochem 2001;109:350–353.
  39. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M: Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression, a prospective study. J Psychiatr Res 2001;35:83–94.
  40. Reynolds JL, Ignatowski TA, Sud R, Spengler RN: An antidepressant mechanism of desipramine is to decrease tumor necrosis factor-alpha production culminating in increases in noradrenergic neurotransmission. Neuroscience 2005;133:519–531.
  41. Taylor JM, Pollard JD: Soluble TNFR1 inhibits the development of experimental autoimmune neuritis by modulating blood-nerve-barrier permeability and inflammation. J Neuroimmunol 2007;183:118–124.
  42. Tulner DM, Smith ORF, de Jonge P, Van Melle JP, Slomp J, Storm H, Quere M, den Boer JA, Honig A, Korf J: Circulating cerebral S100B is associated with depressive symptoms following myocardial infarction. Neuropsychobiology 2009;59:87–95.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50